Group items tagged

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

The National Health Service (NHS) has said that the roll-out of blood-thinning drugs has helped save thousands of lives. In January 2022, the NHS launched a drive to rapidly expand the use of life-saving direct oral anticoagulants (DOACs) in people who are at increased risk of strokes. Since then, more than 24 million prescriptions have been given to such patients and around 460,000 more people have started taking the drugs. This prevented an estimated 17,000 strokes and 4,000 deaths in the last 18 months, as revealed by the new NHS data. Amanda Pritchard, the NHS chief executive, hailed the "lifesaving NHS rollout" at the King's Fund annual conference. It is part of a major NHS drive on "prevention" - to catch more killer conditions earlier and save more lives.

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

More than 80 per cent of pharmacy organisations have received the Department for Work and Pensions (DWP) functionality for Real Time Exemption Checking (RTEC). The NHS Business Services Authority (NHSBSA) has confirmed RTEC has been rolled out gradually, in phases. Contractors first received RTEC for use with processing NHSBSA exemptions. RTEC allows pharmacy teams to digitally check if patients are eligible for free NHS prescriptions because they hold a specific exemption. The rollout of the DWP inclusion in RTEC means patients found to be exempt via RTEC no longer need to complete an exemption declaration on an EPS token, saving time for patients and pharmacy teams. David Broome, a community pharmacy contractor in Leeds and PSNC regional representative said: "The rollout of the DWP for our pharmacy team has been a positive development, helping reduce the amount of paperwork that my team and patients have to deal with and in turn the environmental impact of our operations. Whereas I used to send my paperwork bundle to the NHSBSA in a large box, I now send this in an envelope!" Contractors can access and confirm their acceptance of the RTEC user agreement via the RTEC registration form in the NHSBSA's Manage Your Service (MYS) portal.

Hundreds of children in England are set to benefit from a treatment for cystic fibrosis - Kaftrio, after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) confirmed an extension to its licence. With the licence extension, more than 1,300 children in England with cystic fibrosis, aged six to 11, are newly eligible for this treatment, which improves lung function and improves overall quality of life of patients. Earlier, Kaftrio was only licensed for those aged 12 and above. British patients were the first in Europe to benefit from Kaftrio, when NHS England secured a landmark deal in June 2020. NHS chief executive Amanda Pritchard said: "Since NHS staff delivered one of the fastest rollouts of Kaftrio in the world just over a year ago, the lives of thousands of patients with cystic fibrosis have been transformed. "Innovative treatments like Kaftrio are life-changing for patients and their families, and that is why the NHS has done all it can since we secured the deal for Kaftrio to ensure patients benefit as soon as possible.

NHS Somerset is aiming to grow its referral rate through GP Community Pharmacist Consultation Service (GP CPCS) to between 4,000 to 6,000 patients a month. Since June 2021 GPs in Somerset have successfully referred around 1,000 patients a month through the Somerset GP Community Pharmacist Consultation Service (GP CPCS) Currently, 59 of NHS Somerset's 64 GP practices and all of Somerset's 102 community pharmacists are using the Somerset GP CPCS. NHS Somerset found that providing the right training for GPs and for reception staff and practice managers was key to a smooth rollout and uptake of the service. As was making sure the technology worked when making referrals from general practice to community pharmacists. NHS Somerset is using software called Patient Access Connect, which seamlessly integrates with the EMIS Web GP system used in Somerset, to give practices a quick and easy way to capture the patient information needed to deliver a referral.

NHS England will collaborate with "a number of system suppliers" to increase the number of trusts using electronic prescription service (EPS) over the next few years. Nishali Patel, clinical lead for digital medicines at NHS England, announced it during the Clinical Pharmacy Congress, held at the Excel, London, on Friday, 10 May 2024. According to Nishali, at least half of all NHS secondary care trusts could be using EPS by 2026. This digital service allows prescribers to send prescriptions electronically to a patient-nominated pharmacy. It is widely used in primary care, where over 95 per cent of prescriptions are now electronically generated. NHS recently extended the service to secondary care settings.

In a groundbreaking move towards modernising healthcare, England's National Health Service (NHS) has successfully implemented digital prescriptions, as reported by the World Health Organization (WHO) in its latest regional digital health report. Since January 2024, patients across England have had access to their prescription information through the NHS App, marking a significant leap in healthcare accessibility and efficiency. With over 33 million registered users, representing 75 per cent of the adult population, the NHS App has become a vital tool in managing healthcare online. The introduction of digital prescriptions allows users to order repeat prescriptions online without the need for a GP visit. This innovation has witnessed a surge in digital requests, with over 3.1 million repeat prescriptions processed monthly.

To lead the way in modernizing the UK's healthcare, the National Health Service (NHS) digitized the prescriptions. WHO mentioned this in their current digital regional report. Since January 2024, the NHS App in England has offered patients the opportunity to see statistics about their prescriptions. This represents a gigantic step in the area of healthcare which can be categorized as another stage in healthcare accessibility and efficiency. Over 33 million residents have taken the NHS app enabling the users to be 75% of the adult population. The app helps in online management of their health. The use of digital prescriptions enables patients to order repeated prescriptions online, in which they would past getting an appointment a GP.

The Pharmaceutical Services Negotiating Committee (PSNC) has published a guidance for community pharmacies to help them in the implementation of the new Prescription Prepayment Certificate (PPC) for hormone replacement therapy (HRT). The new policy will rollout from 1 April 2023, patients who are not already exempt from NHS prescription charges will be able to purchase an annual HRT PPC for the cost of two single prescription charges Major concern raised by PSNC is that the NHS systems have not kept pace with policy, as the certificate is launching without the IT in place to support it. PSNC has been clear that this is totally unacceptable, including raising this with Ministers directly and warning them that introducing the PPC without this infrastructure risks causing confusion for some patients and adding to the burden for pharmacy teams. "Government recognises the challenges but is determined to move forwards with the policy, said the committee. "DHSC has recognised the impact this will have on pharmacies and we are still pressing for appropriate financial compensation. We have also sought guidance for GPs, and now published our own guidance to try to make the launch go as smoothly as it can for pharmacy teams."

The NHS on Thursday (May 5) said it has rolled out the arthritis drug baricitinib for seriously ill Covid patients. The Recovery trial, conducted by the NHS and University of Oxford, found that 13 per cent fewer severely ill patients died of Covid when treated with the drug compared to existing treatment options. Typically used to treat arthritis to reduce pain and inflammation, baricitinib can now be given to hospitalised Covid patients in addition to current treatments, and clinical studies show that this can provide benefits on top of existing treatment. The NHS has led the rollout of Covid medicines, from the discovery of dexamethasone as the world's first effective treatment, to the first vaccination outside of a clinical trial in December 2020. The NHS said baricitinib works by reducing inflammation caused by Covid-19 by blocking signals to the immune system that are causing it to attack the body.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.

Deviating from the initial schedule to kick off the flu and Covid-19 vaccination campaigns in October, the NHS England has announced that the autumn vaccination drive will commence sooner than expected in England, starting on September 11. This decision was taken as a precaution in response to a new Covid-19 variant. The precautionary measure is being taken as the Department of Health and Social Care and the UK Health Security Agency examined the variant BA.2.86, which was first detected in the UK on Friday, August 18, 2023, the NHSE said on Aug. 30. While NHS England had previously announced that vaccinations for both NHS programmes would begin on October 2 for residents of older adult care homes, appointments for other eligible groups were scheduled for the following week, starting on October 7. This decision prompted community pharmacy leaders to denounce the delayed start of the flu service as 'unacceptable'.

Local pharmacists in England can now evaluate and provide treatment for patients with uncomplicated urinary tract infections (UTIs) in women under the age of 65, without the need for a GP appointment. The 'ByeByeUTI' scheme has been expanded across the country, following a successful pilot across North East and North Cumbria. More than 30,000 women have been treated for uncomplicated urinary tract infections at local pharmacies since the pilot scheme was launched in July 2022 as part of the NHS and government's primary care access recovery plan, according to NHS England. The expansion of pharmacy services not only enhances patients' access to care but also frees up tens of thousands of GP appointments at the same time. Dr Faisel Baig, Medical Director for Primary Care, NHS England North East and Yorkshire, said that the rollout of this service across the whole region will enable many more women to receive "faster and easier" access to advice and treatment.

In a significant move aimed at improving patient care and alleviating hospital pressures, the National Health Services (NHS) has expanded its same day emergency care services across the UK. This has resulted in thousands more individuals receiving rapid tests and treatment, effectively avoiding overnight hospital stays. Recent data paints a promising picture, revealing an 11 per cent increase in the number of patients discharged on the same day they were admitted as emergencies. This advancement translates to several patients receiving urgent care within hours, subsequently freeing up beds for others in need. Over the past year alone, an impressive 206,446 more patients have been discharged on the same day, amounting to 2,024,129 individuals in the year leading up to January 2024, compared to 1,817,683 in the preceding year. The successful rollout of same day emergency care to every hospital in England has played a pivotal role in easing bed congestion and reducing hospital admissions by up to 30 per cent in certain NHS Trusts.

The nationwide implementation of the Pharmacy First service is viewed as a significant development that benefits pharmacies, primary care, and the broader National Health Service (NHS). Pharmacy teams are striving to ensure its success despite challenges within the industry landscape. However, not all pharmacists are able to reap the benefits from it. Recently, two members of Numark shared their experiences of how the scheme is impacting their pharmacies. Graham Phillips, who owns Letchworth Pharmacy in Hertfordshire, revealed that patients are responding favourably to the service. "It's all good, people are just delighted to have easier access to care," he said. In its first month, Letchworth Pharmacy provided around 100 consultations, and Phillips envisions that as the service matures, they will be able to conduct an average of 200 interventions per week. "That will make it financially viable for us and mean that we're acting at scale from an NHS perspective. That's 200 GP appointments we've freed up in a week - that's a huge capability and capacity bump for the NHS," he added. Graham credits part of his success with Pharmacy First to the strong relationship he has established with local GPs in his area.

The National Pharmacy Association (NPA) is calling on NHS England and its member to pause and reflect before further implementing the pharmacy contraception service. NPA board met on Tuesday (25 April) to discuss the Pharmacy Contraception Service and the board decided that - with the community pharmacy sector at breaking point - it cannot support the immediate roll out of this service. The association believes that with no new funding for the service, and all existing funds in effect already allocated to other pharmacy activity, any payments to the sector for delivery of the oral contraception service will ultimately be clawed back by NHS England. Tweeting after the meeting yesterday, the NPA said: "We can't tell pharmacy owners what they can and can't do. But we can tell them the facts; fact number one is that with no new funding currently available everyone will be a loser from the implementation of this service on the current terms." NPA Vice-Chair Jay Badenhorst added: "We cannot be expected to take on more and more services without the increase in funding necessary to deliver them effectively. Meanwhile, taking on additional work when current workload already exceeds capacity risks impacting negatively on the overall quality of care people experience in pharmacies. We still believe this could, in future, be a great new pharmacy service, but not without the extra funding necessary to deliver it safely and effectively. We want to offer women this extra support, but if it's worth doing it's worth doing properly."

The Digital Medicines Transformation Portfolio (DMTP) was able to deliver the electronic prescription service (EPS) in Wales - just 20 months after starting the project - with support from key partners in the NHS and industry. Patients in Rhyl were the first to benefit from the new service, which allows GPs to send prescriptions electronically to the patient's choice of community pharmacy, without the need for a paper form. The new EPS service is currently in a live testing phase, with a phased roll out across Wales expected from January 2024. DMTP, which is hosted by Digital Health and Care Wales (DHCW) has worked closely with NHS England, who provided the core EPS platform that has been developed for use in Wales. NHS Wales Shared Services Partnership has also made a major contribution in the project, incorporating digital reimbursement to pharmacies and putting security measures in place.

It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant. "It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months. "That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.

Pharmacy owners can proceed with vaccinating patients who have already scheduled their flu vaccination appointments for September, NHS England has said. However, as announced earlier, the official rollout of the vaccination service will commence from October. Pharmacies will receive compensation for conducting appointments in the upcoming month, NHSE stated in a letter addressed to systems, community pharmacies, and general practices. "Payment for vaccinations will ordinarily only be made following the service commencement date. However, we understand that some firm commitments and appointments have already been made, so where this is the case and the patient wishes to receive flu vaccination in September, NHS England will permit payment claims to be submitted," NHSE said. Care home residents and staff will be eligible for the vaccine starting Oct. 2, while all other patients will commence receiving their vaccinations on Oct 7. This news is a significant relief for pharmacy owners, as they won't have to reschedule appointments due to NHSE's one-month service delay.